EP1003896A1 - Vecteur de baculovirus modifie par coque de proteine s'utilisant en genotherapie - Google Patents

Vecteur de baculovirus modifie par coque de proteine s'utilisant en genotherapie

Info

Publication number
EP1003896A1
EP1003896A1 EP98947386A EP98947386A EP1003896A1 EP 1003896 A1 EP1003896 A1 EP 1003896A1 EP 98947386 A EP98947386 A EP 98947386A EP 98947386 A EP98947386 A EP 98947386A EP 1003896 A1 EP1003896 A1 EP 1003896A1
Authority
EP
European Patent Office
Prior art keywords
vector
vector according
virus
sequence
baculovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98947386A
Other languages
German (de)
English (en)
Inventor
Christian Hofmann
Michael Strauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
HepaVec AG fur Gentherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HepaVec AG fur Gentherapie filed Critical HepaVec AG fur Gentherapie
Publication of EP1003896A1 publication Critical patent/EP1003896A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un vecteur de baculovirus modifié par coque de protéine s'utilisant en génothérapie et s'appliquant à la médecine, la biotechnologie et la technique génique. L'invention vise à la construction d'un vecteur de baculovirus présentant une stabilité élevée dans le sang, par modification de l'enveloppe virale et permettant de transférer et d'établir des gènes thérapeutiques, indépendamment de leur taille, dans des cellules mamméliennes, de manière hautement spécifique et efficace. Le vecteur doit pouvoir s'utiliser en génothérapie chez l'homme. Le vecteur obtenu selon l'invention comprend un virus d'insecte, de préférence un représentant des baculovirus ou d'un virus de la polyhédrose nucléaire, contenant les constituants suivants: des coques de protéines de virus modifiées, une séquence d'ADN thérapeutique, un promoteur adapté à l'expression génique et éventuellement une séquence d'établissement.
EP98947386A 1997-08-15 1998-08-05 Vecteur de baculovirus modifie par coque de proteine s'utilisant en genotherapie Withdrawn EP1003896A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1997135593 DE19735593C2 (de) 1997-08-15 1997-08-15 Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie
DE19735593 1997-08-15
PCT/DE1998/002255 WO1999009193A1 (fr) 1997-08-15 1998-08-05 Vecteur de baculovirus modifie par coque de proteine s'utilisant en genotherapie

Publications (1)

Publication Number Publication Date
EP1003896A1 true EP1003896A1 (fr) 2000-05-31

Family

ID=7839201

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98947386A Withdrawn EP1003896A1 (fr) 1997-08-15 1998-08-05 Vecteur de baculovirus modifie par coque de proteine s'utilisant en genotherapie

Country Status (6)

Country Link
EP (1) EP1003896A1 (fr)
JP (1) JP2003530064A (fr)
CA (1) CA2300362A1 (fr)
DE (1) DE19735593C2 (fr)
ES (1) ES2150894T1 (fr)
WO (1) WO1999009193A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183993B1 (en) * 1996-09-11 2001-02-06 The General Hospital Corporation Complement-resistant non-mammalian DNA viruses and uses thereof
GB0012997D0 (en) * 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
US6607912B2 (en) 2000-08-11 2003-08-19 Boyce Thompson Institute For Plant Research, Inc. GP64-null baculoviruses pseudotyped with heterologous envelope proteins
CA2440342A1 (fr) 2001-03-12 2002-09-19 Ark Therapeutics Ltd. Vecteurs viraux pseudotypes par l'avidine et leur utilisation
WO2002096469A2 (fr) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Transfert genique de vecteur viral
GB0119852D0 (en) * 2001-08-15 2001-10-10 Univ York Baculovirus
US6863884B2 (en) 2002-05-01 2005-03-08 Cell Genesys, Inc. Pseudotyped retroviral vectors
AU2003266628A1 (en) * 2002-09-25 2004-04-19 Osaka Industrial Promotion Organization Baculovirus vector, method of constructing baculovirus vector and gene transfer method
US7416890B2 (en) 2002-09-25 2008-08-26 Osaka Industrial Promotion Organization Baculovirus vector, method of producing thereof and method of gene transfer
NZ586034A (en) 2004-02-02 2011-10-28 Ambrx Inc Modified human growth hormone polypeptides and their uses
NZ582684A (en) 2004-06-18 2011-05-27 Ambrx Inc Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
GB0425739D0 (en) * 2004-11-23 2004-12-22 Procure Therapeutics Ltd Humanised baculovirus 2
KR20070100299A (ko) 2004-12-22 2007-10-10 암브룩스, 인코포레이티드 재조합 인간 성장 호르몬의 발현 및 정제 방법
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
CN102719366B (zh) 2004-12-22 2014-07-16 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
SG161209A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
WO2006133088A2 (fr) 2005-06-03 2006-12-14 Ambrx, Inc. Molecules d'interferons humains ameliorees et utilisations de celles-ci
JP2009520949A (ja) 2005-11-16 2009-05-28 アンブルックス，インコーポレイテッド 非天然アミノ酸を含んでいる組成物および方法
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
EP2069396B1 (fr) 2006-09-08 2015-10-21 Ambrx, Inc. Polypeptide plasmatique humain modifie ou squelettes de fc et leurs utilisations
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
WO2008137471A2 (fr) 2007-05-02 2008-11-13 Ambrx, Inc. Polypeptides d'interféron bêta modifiés et leurs utilisations
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
CA2712606A1 (fr) 2008-02-08 2009-08-13 Ambrx, Inc. Polypeptides leptine modifies et leurs utilisations de marburg
PL3225248T3 (pl) 2008-07-23 2023-11-27 Ambrx, Inc. Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
NZ601659A (en) 2008-09-26 2014-02-28 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
MX2012006980A (es) 2009-12-21 2012-07-17 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos.
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2016059911A1 (fr) * 2014-10-17 2016-04-21 国立大学法人金沢大学 Vaccin antipaludéen
DK3412302T3 (da) 2014-10-24 2021-07-12 Bristol Myers Squibb Co Modificerede fgf-21-polypeptider og anvendelser deraf
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4407859C1 (de) * 1994-03-04 1995-03-02 Max Planck Gesellschaft Vektor für die leberspezifische Gentherapie
EP0785803A4 (fr) * 1994-09-23 2000-08-02 Gen Hospital Corp Utilisation d'un virus a adn non mammalien en vue de l'expression d'un gene exogene dans une cellule mammalienne
US5750383A (en) * 1996-05-14 1998-05-12 Boyce Thompson Institute For Plant Research, Inc. Baculovirus cloning system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9909193A1 *

Also Published As

Publication number Publication date
DE19735593A1 (de) 1999-02-18
DE19735593C2 (de) 1999-08-26
WO1999009193A1 (fr) 1999-02-25
ES2150894T1 (es) 2000-12-16
CA2300362A1 (fr) 1999-02-25
JP2003530064A (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
DE19735593C2 (de) Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie
DE69829471T2 (de) Auf lentivirus basierende gentransfer-vektoren
DE69333471T2 (de) Erzielbare vektorenpartikel
DE69518910T3 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
DE60034478T2 (de) Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
DE69635172T2 (de) Rekombinanter MVA Virus und seine Verwendung
DE69634300T2 (de) Gentherapie mit hilfe von schaf-adenoviralen vektoren
DE69834936T2 (de) Vektor zur gewebespezifischen replikation und expression
WO1995029993A1 (fr) Vecteur d'apport de genes utilisant un adn plasmidique encapsule dans un adenovirus et une lignee cellulaire d'encapsidation
DE69936577T2 (de) Lentivirale Verpackungszellen
EP0961830A1 (fr) VECTEURS D'EXPRESSION ET PROCEDES D'EXPRESSION $i(IN VIVO) DE POLYPEPTIDES THERAPEUTIQUES
MX9709549A (es) Adenovirus recombinantes, su uso para preparar aav, linea celular complementaria y composiciones farmaceuticas que los contienen.
CA2224114A1 (fr) Chromosome synthetique de mammifere et procedes de construction de celui-ci
EP0723460A1 (fr) Therapie genique concernant le systeme nerveux
KR100484883B1 (ko) 바이러스성입자를생산하는캡슐화세포
DE69725882T2 (de) Adenovirus e4 proteine für induktion von zelltod
DE4407859C1 (de) Vektor für die leberspezifische Gentherapie
DE69627644T2 (de) Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
EP0839205A1 (fr) Vecteur d'expression d'adenovirus hepato-specifique
EP0716711A1 (fr) Vecteur pour la therapie genique du foie
DE19807265C2 (de) Adenoviraler Transfervektor für den Gentransport einer DNA-Sequenz
EP0955374B1 (fr) Vecteurs retroviraux pour le transfer de gènes
EP0889968A2 (fr) Sequences de regulation positive de l'antigene prostatique specifique et utilisations de ces sequences
EP1544305A1 (fr) Adapteur pour la liaison d'une substance sur la paroi cellulaire
EP1000167B2 (fr) Production de proteines mutantes humaines dans des cellules humaines par recombinaison homologue

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT CH DE ES FR GB IE IT LI NL SE

GBC Gb: translation of claims filed (gb section 78(7)/1977)
EL Fr: translation of claims filed
TCNL Nl: translation of patent claims filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: BA2A

Ref document number: 2150894

Country of ref document: ES

Kind code of ref document: T1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEVELOGEN AKTIENGESELLSCHAFT FUER ENTWICKLUNGSBIOL

IECL Ie: translation for ep claims filed
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040229